Literature DB >> 32003679

Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Margaret Spinosa1, Jonathan G Stine2,3.   

Abstract

Nonalcoholic fatty liver disease is the leading cause of liver disease worldwide. It has expansive extrahepatic morbidity and mortality including increased rates of both cardiovascular disease and venous thromboembolism. Derangements in primary, secondary and tertiary hemostasis are found in nonalcoholic fatty liver disease independent of those ascribed to end-stage liver disease. The abnormalities across all stages of hemostasis explain the increased rates of clinically relevant thrombotic events, including pulmonary embolism, deep vein thrombosis and portal vein thrombosis, which on an epidemiologic basis appears to be independent of obesity and other traditional venous thromboembolic risk factors. However, given the complex interaction between obesity, body composition and nonalcoholic fatty liver disease and the potential for exercise to benefit all three, more research is needed to further define the role of each in contributing to the prohemostatic state of nonalcoholic fatty liver disease in order to improve patient oriented outcomes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Thrombosis; exercise; hypercoagulable; liver transplantation; nonalcoholic steatohepatitis; thromboembolic.

Mesh:

Year:  2020        PMID: 32003679      PMCID: PMC7226677          DOI: 10.2174/1381612826666200131101553

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  109 in total

Review 1.  AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine.

Authors:  M L Pollock; B A Franklin; G J Balady; B L Chaitman; J L Fleg; B Fletcher; M Limacher; I L Piña; R A Stein; M Williams; T Bazzarre
Journal:  Circulation       Date:  2000-02-22       Impact factor: 29.690

2.  Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.

Authors:  Jonathan G Stine; Neeral L Shah; Curtis K Argo; Shawn J Pelletier; Stephen H Caldwell; Patrick G Northup
Journal:  Liver Transpl       Date:  2015-07-01       Impact factor: 5.799

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 4.  Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.

Authors:  Sanjaya K Satapathy; Arun J Sanyal
Journal:  Semin Liver Dis       Date:  2015-09-17       Impact factor: 6.115

5.  ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.

Authors:  Hiroaki Takaya; Masahito Uemura; Yoshihiro Fujimura; Masanori Matsumoto; Tomomi Matsuyama; Seiji Kato; Chie Morioka; Hiromichi Ishizashi; Yuji Hori; Masao Fujimoto; Tatsuhiro Tsujimoto; Hideto Kawaratani; Masahisa Toyohara; Norio Kurumatani; Hiroshi Fukui
Journal:  Hepatol Res       Date:  2012-01-31       Impact factor: 4.288

6.  Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

Authors:  Cecilia Söderberg; Per Stål; Johan Askling; Hans Glaumann; Greger Lindberg; Joel Marmur; Rolf Hultcrantz
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 7.  A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.

Authors:  M H Prins; J Hirsh
Journal:  Arch Intern Med       Date:  1991-09

8.  NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo; Christopher P Day
Journal:  Obesity (Silver Spring)       Date:  2008-03-27       Impact factor: 5.002

9.  Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.

Authors:  Marianne Tang Severinsen; Søren Risom Kristensen; Søren Paaske Johnsen; Claus Dethlefsen; Anne Tjønneland; Kim Overvad
Journal:  Circulation       Date:  2009-10-26       Impact factor: 29.690

10.  Outcome after liver transplantation for NASH cirrhosis.

Authors:  S M Malik; M E deVera; P Fontes; O Shaikh; J Ahmad
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

View more
  6 in total

1.  Metabolic Disorders and Risk of Portal Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Jiao Li; Qiong Wang; Mei Yang; Xiaobin Sun
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

Review 2.  Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.

Authors:  Yuping Zeng; He He; Zhenmei An
Journal:  Dis Markers       Date:  2022-06-29       Impact factor: 3.464

3.  NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.

Authors:  Jonathan G Stine; Ian R Schreibman; Alison J Faust; Jessica Dahmus; Benjamin Stern; Christopher Soriano; Gloriany Rivas; Breianna Hummer; Scot R Kimball; Nate R Geyer; Vernon M Chinchilli; Rohit Loomba; Kathryn Schmitz; Christopher Sciamanna
Journal:  Hepatology       Date:  2022-01-22       Impact factor: 17.298

4.  Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.

Authors:  Stefano Ballestri; Alessandro Mantovani; Enrica Baldelli; Simonetta Lugari; Mauro Maurantonio; Fabio Nascimbeni; Alessandra Marrazzo; Dante Romagnoli; Giovanni Targher; Amedeo Lonardo
Journal:  Diagnostics (Basel)       Date:  2021-01-09

Review 5.  Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications.

Authors:  Doris Ogresta; Anna Mrzljak; Maja Cigrovski Berkovic; Ines Bilic-Curcic; Sanja Stojsavljevic-Shapeski; Lucija Virovic-Jukic
Journal:  J Clin Transl Hepatol       Date:  2022-01-12

6.  Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.

Authors:  Marta Bellesini; Matteo Bianchin; Chiara Corradi; Marco Paolo Donadini; Emanuel Raschi; Alessandro Squizzato
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.